Adaptimmune Therapeutics Plc (ADAP) Insider Trading
- $80,274,368.40
- $25,072,315.08
- Sept. 1, 2023
- Adrian Rawcliffe
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Jan. 13, 2020 | Director | 300,000 | $4.67 | Sell | $1,401,000.00 | |
| Jan. 6, 2020 | CEO | 5,900 | $1.20 | Sell | $7,080.00 | |
| Jan. 6, 2020 | Insider | 1,148 | $1.20 | Sell | $1,377.60 | |
| Jan. 6, 2020 | COO | 3,731 | $1.20 | Sell | $4,477.20 | |
| Aug. 6, 2019 | Insider | 11,043 | $2.06 | Sell | $22,748.58 | |
| Jan. 14, 2019 | CFO | 3,084 | $5.37 | Sell | $16,561.08 | |
| Jan. 14, 2019 | CTO | 1,514 | $5.37 | Sell | $8,130.18 | |
| Jan. 14, 2019 | Insider | 3,028 | $5.37 | Sell | $16,260.36 | |
| Jan. 14, 2019 | COO | 2,271 | $5.37 | Sell | $12,195.27 | |
| Dec. 17, 2018 | Director | 47,280 | $0.84 | Buy | $39,715.20 | |
| Oct. 1, 2018 | Insider | 25,000 | $13.79 | Sell | $344,750.00 | |
| Sept. 7, 2018 | Director | 12,000,000 | $1.67 | Buy | $20,040,000.00 | |
| Sept. 7, 2018 | Major Shareholder | 3,000,000 | $1.67 | Buy | $5,010,000.00 | |
| Aug. 29, 2018 | Insider | 25,000 | $10.25 | Sell | $256,250.00 | |
| June 6, 2018 | Director | 18,700 | $13.56 | Sell | $253,572.00 | |
| June 4, 2018 | Director | 17,100 | $13.57 | Sell | $232,047.00 | |
| June 1, 2018 | Director | 171,000 | $13.51 | Sell | $2,310,210.00 | |
| May 30, 2018 | Director | 121,000 | $13.52 | Sell | $1,635,920.00 | |
| May 14, 2018 | Director | 10,300 | $13.50 | Sell | $139,050.00 | |
| March 29, 2018 | Director | 1,048,067 | $11.50 | Sell | $12,052,770.50 | |
| March 27, 2018 | Major Shareholder | 6,571,164 | $1.92 | Buy | $12,616,634.88 | |
| March 26, 2018 | Director | 571,164 | $1.90 | Buy | $1,085,211.60 | |
| March 23, 2018 | Major Shareholder | 1,268,508 | $1.91 | Buy | $2,422,850.28 | |
| March 22, 2018 | Director | 869,574 | $1.90 | Buy | $1,652,190.60 | |
| March 21, 2018 | Major Shareholder | 104,844 | $1.81 | Buy | $189,767.64 | |
| March 20, 2018 | CFO | 600,000 | $1.71 | Sell | $1,026,000.00 | |
| March 27, 2017 | Director | 1,190,476 | $4.20 | Buy | $4,999,999.20 | |
| March 27, 2017 | Major Shareholder | 12,870,000 | $0.70 | Buy | $9,009,000.00 | |
| May 24, 2016 | Director | 1,712,400 | $10.42 | Buy | $17,843,208.00 | |
| May 19, 2016 | Director | 15,000 | $1.56 | Buy | $23,400.00 | |
| May 18, 2016 | Director | 45,000 | $1.53 | Buy | $68,850.00 |
Insiders are both buying and selling Adaptimmune Therapeutics Plc stock.
The insider traders at Adaptimmune Therapeutics Plc are: Adrian Rawcliffe, John Lunger, William C. Bertrand, Jr., William C Bertrand Jr, Orbimed Advisors Llc, Enterprise Associates 14 New, Peter A Thompson, Gavin Wood, Gwendolyn Knowlt Binder-Scholl, Elliot Norry, James Noble, Charles Elliott Sigal, David M Mott, Lawrence M. Alleva, Rafael Amado, Ali Behbahani, Garry E Menzel, Peter W Sonsini, Ravi Viswanathan, and Cintia Piccina
The most active insider trader at Adaptimmune Therapeutics Plc is Adrian Rawcliffe with 21 trades.
Orbimed Advisors Llc has sold the most Adaptimmune Therapeutics Plc stock with a total value of $14,870,124.50.
Ali Behbahani has bought the most Adaptimmune Therapeutics Plc stock with a total value of $40,080,000.00.
The most recent insider trade for Adaptimmune Therapeutics Plc was on Sept. 1, 2023.
The single biggest insider buy for Adaptimmune Therapeutics Plc was from Ali Behbahani with a total value of $20,040,000.00 on Sept. 7, 2018.
The single biggest insider sell for Adaptimmune Therapeutics Plc was from Orbimed Advisors Llc with a total value of $12,052,770.50 on March 29, 2018.